LL-37 vs Thymosin Alpha-1

LL-37: Human antimicrobial peptide with broad-spectrum pathogen defense and wound-healing activity. Typical dose 50-100 mcg. Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. Both fall under the Healing & Recovery and Immune categories.

Stacking LL-37 with Thymosin Alpha-1 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

LL-37 is typically dosed: Once daily (SubQ) for Antimicrobial support; Once daily near affected area for Wound healing support. Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support.

LL-37: Not FDA approved for human use. Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted.